Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q1 2024 earnings with a GAAP EPS of $(0.20), meeting analyst estimates but showing a 17.65% decrease from the previous year. Sales were $1.130M, missing estimates by 19.33% but marking a significant increase from the previous year's $24K.
May 02, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lexicon Pharmaceuticals reported a GAAP EPS of $(0.20) for Q1 2024, in line with estimates but down from last year, and sales of $1.130M, missing estimates but significantly higher than last year's.
The EPS meeting estimates but showing a decrease from the previous year could have a neutral to slightly negative impact on investor sentiment. However, the significant increase in sales compared to the previous year indicates strong growth, potentially offsetting concerns about the EPS performance. The miss on sales estimates might concern some investors, but the overall growth trajectory is positive.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100